Prefusion PIV F immunogens and their use

US11845778B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• Institute for Research in Biomedicine · CH

Inventors

• Baoshan Zhang · Bethesda, US
• Guillaume Stewart-Jones · Cambridge, US
• John Mascola · Rockville, US
• Kai Xu · Bethesda, US
• Gwo-Yu Chuang · Rockville, US
• Li Ou · Bethesda, US
• Peter Kwong · Washington, US
• Yaroslav Tsybovsky · Jefferson, US
• Wing-Pui Kong · Germantown, US
• Aliaksandr Druz · Germantown, US
• Davide Corti · Bellinzona, CH
• Antonio Lanzavecchia · Bellinzona, CH

Key dates

• Filing date: Jul 16, 2021
• Grant date: Dec 19, 2023
• Expiry date: Dec 16, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18734
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.